Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aclaris Therapeutics, Inc.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to comprehend and be willing to sign the Institutional Review Board (IRB)-approved participant informed consent form prior to administration of any study-related procedures.
Participant must have stable HS.
Total abscesses and/or nodule (AN) count of ≥5 at Baseline visit.
HS lesions present in at least 2 distinct anatomical areas at Screening and Baseline.
You may not be if
Participant has a history of active skin disease other than HS that could interfere with the assessment of HS.
Participant has an uncontrolled non-immunoinflammatory disease that may place the participant at increased risk during the study or impact the interpretation of results, e.g., previous malignancy, previous venous thromboembolism.
Participant has experience with \>2 biologics, \>1 Janus kinase (JAK) inhibitor, or a combination of 1 biologic experience and 1 JAK inhibitor.
Are currently receiving corticosteroids at doses greater than 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of the Screening visit.
